

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-30. (canceled)

31. (previously presented) A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and having been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

32. (previously presented) A preparation as set forth in claim 31, said preparation consisting essentially of vWF propeptide.

33-34. (canceled)

35. (previously presented) A preparation as set forth in claim 31, further comprising a hemostasis protein.

36. (previously presented) A preparation as set forth in claim 35, wherein said hemostasis protein is a blood factor.

37. (previously presented ) A preparation as set forth in claim 36, wherein said blood factor is selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, and blood factors with factor VIII inhibitor bypassing activity.

38. (canceled)

39. (previously presented) A preparation as set forth in claim 31, further comprising a platelet component.

40. (previously presented) A preparation as set forth in claim 39, wherein said platelet component is at least one component selected from the group consisting of collagen, a platelet glycoprotein, a platelet, fibrinogen, fibrin, heparin and a derivative thereof.

41. (previously presented) A preparation as set forth in claim 31, further comprising a phospholipid.

42. (canceled)

43. (previously presented) A preparation as set forth in claim 31, further comprising a pharmaceutically acceptable carrier.

44. (previously presented) A preparation as set forth in claim 31, wherein said vWF propeptide is a recombinant vWF propeptide.

45-63. (canceled)

64. (previously presented) A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising von Willebrand Factor (vWF) propeptide that is at least 80% pure and has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

65. (previously presented) A preparation as set forth in claim 64, wherein the vWF propeptide is at least 95% pure.

66. (previously presented) A preparation as set forth in claim 31, further comprising at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component and a phospholipid.

67. (canceled)

68. (currently amended) A preparation as set forth in claim 77, wherein said pro-vWF is a recombinant pro-vWF.

69. (currently amended) A preparation as set forth in claim 77, further comprising factor VIII, said pro-vWF being complexed to said factor VIII.

70-71. (canceled)

72. (previously presented) A pharmaceutical preparation as set forth in claim 31, wherein the preparation is formulated for parenteral administration.

73. (canceled)

74. (previously presented) The pharmaceutical preparation as set forth in claim 64, wherein the vWF propeptide is at least 90% pure.

75. (previously presented) A pharmaceutical preparation for treating blood coagulation disorders, the preparation comprising at least 30 nM von Willebrand Factor (vWF) propeptide and having been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

76. (previously presented) The pharmaceutical preparation as set forth in claim 75, wherein the preparation comprises at least 50 nM vWF propeptide.

77. (previously presented) A pharmaceutical preparation for treating blood coagulation disorders, the preparation comprising at least 10 nM pro-von Willebrand Factor (pro-vWF).

78. (previously presented) The pharmaceutical preparation as set forth in claim 77, wherein the preparation comprises at least 100 nM pro-vWF.